A Multicenter, parallel-group, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson's disease patients with motor complications not well controlled on medical treatment

Trial Profile

A Multicenter, parallel-group, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson's disease patients with motor complications not well controlled on medical treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms TOLEDO
  • Sponsors Britannia Pharmaceuticals; STADA Arzneimittel
  • Most Recent Events

    • 09 Aug 2017 This trial has been completed in Spain (End date: 2017-06-09), as per European Clinical Trials Database record.
    • 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
    • 08 Jun 2017 Primary endpoint has been met. (Absolute change in time spent OFF from baseline to the end of 12 weeks treatment period based on patient diaries) as per results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top